Tibolone and osteoporosis
| Autor: | Andreja Glisic, Verica Milosevic, Ubavka Radivojevic, Gordana Lazovic, Andrija Lazovic, Katarina Jeremic |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Norpregnenes Osteoporosis Population Tibolone Bone Density Internal medicine medicine Vitamin D and neurology Humans Prospective Studies Prospective cohort study education Osteoporosis Postmenopausal Aged Gynecology Bone mineral education.field_of_study Lumbar Vertebrae Bone Density Conservation Agents business.industry Femur Neck musculoskeletal neural and ocular physiology Obstetrics and Gynecology General Medicine Middle Aged musculoskeletal system medicine.disease Osteopenia Menopause Female business medicine.drug |
| Zdroj: | Archives of gynecology and obstetrics. 276(6) |
| ISSN: | 0932-0067 |
| Popis: | We conducted a 5-year prospective, observational, controlled study to assess the effects of tibolone 1.25 mg/day on bone mineral density (BMD) in postmenopausal women with osteopenia or osteoporosis. The subjects were 420 women, an average of 66.4 years old, who had been postmenopausal between 8 and 19 years when enrolled in the study. Of the 420 women enrolled, 346 agreed to take tibolone for 5 years. The 74 who refused tibolone took only calcium/vitamin D supplements and served as the control group. BMD was measured in the lumbar spine and total hip region at baseline and annually by dual-energy X-ray absorptiometry (DXA). At the first two follow-up visits, women taking tibolone had a significant increase in BMD at the spine (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink